<DOC>
	<DOCNO>NCT00919919</DOCNO>
	<brief_summary>The objective study confirm efficacy vaginal progesterone least good oral progesterone order protect endometrium uncontrolled proliferation prevent endometrial cancer .</brief_summary>
	<brief_title>Efficacy Tolerability Study Progesterone Vaginal Tablets ( Endometrin® ) Menopausal Women Treated Estrogen</brief_title>
	<detailed_description>Estrogen Replacement Therapy must oppose progesterone order protect endometrium uncontrolled proliferation prevent endometrial cancer , woman intact uterus .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Women candidate Hormone Replacement Therapy due menopausal symptom . Women intact uterus . No menses within 12 month precede screen visit /or FSH &gt; 30 IU/L . Endometrial thickness ≤ 5 mm . Submucosal fibroid/s applying pressure affect endometrial thickness Other medication could affect estrogenic state .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>menopause</keyword>
	<keyword>Endometrial Thickness</keyword>
	<keyword>progesterone</keyword>
</DOC>